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Using Gene Expression Arrays to Elucidate Transcriptional
Profiles Underlying Prolactin Function
Sandra Gass,1 Jessica Harris,2 Chris Ormandy,2 and Cathrin Brisken1,3
Prolactin is an ancient hormone, with different functions in many species. The binding of
prolactin to its receptor, a member of the cytokine receptor superfamily, results in the acti-
vation of different intracellular signaling pathways, such as JAK2/STAT5, MAP kinase, and
PI3K/AKT. How prolactin elicits so many different biological responses remains unclear. Re-
cently, microarray technology has been applied to identify prolactin target genes in different
systems. Here, we attempt to summarize and compare the available data. Our comparison of
the genes reported to be transcriptionally regulated by prolactin indicates that there are few
genes in common between the different tissues. Among the organs studied, mammary and
prostate glands displayed the largest number of overlaps in putative prolactin target genes.
Some of the candidates have been implicated in tumorigenesis. The relevance and validation
of microarray data, as well as comparison of the results obtained by different groups, will be
discussed.
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Prolactin is a peptide hormone, the bulk of which
is secreted by the anterior pituitary gland. In females,
prolactin serum levels are elevated during the luteal
phase of the menstrual cycle (1), they increase dur-
ing late pregnancy and lactation, and peak follow-
ing bouts of nursing (2). It is an ancient hormone,
which plays a role in very different processes in verte-
brates, such as freshwater osmoregulation in fish (3),
nesting behavior in birds, and growth and metamor-
phosis in amphibians (4). Prolactin acts pleiotropi-
cally on a variety of target tissues in mammals (5),
affecting, directly and indirectly, the development
of the mammary gland, the ovaries, the prostate,
and lacrimal glands, the intestine, and the skin. The
hormone binds to the prolactin receptor (PrlR), a
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member of the cytokine receptor family (6), thereby
activating different intracellular signaling pathways
Abbreviations used: 20fi-HSD, 20 alpha-hydroxysteroid dehydro-
genase; 3fl-HSD, 3fl-hydroxysteroid dehydrogenase; bHLH, ba-
sic Helix–Loop–Helix; BRCA1, breast cancer 1; C/EBP, CCAAT
enhancer-binding protein; cDNA, complementary deoxyribonu-
cleic acid; CL, corpus luteum; DNA, deoxyribonucleic acid;
ECM, extracellular matrix; EGF, epidermal growth factor;
EST, expressed sequence tag; GATA3, GATA binding protein 3;
GlyCAM 1, glycosylation-dependent cell adhesion molecule 1;
HB-EGF, heparin-binding epidermal growth factor; HE5, human
epididymal protein 5; IGF-2, insulin-like growth factor 2; IRF-1,
interferon-regulated factor 1; JAK, janus kinase; MAP, mitogen
activated protein; MAS, MicroArray Suite; MEC, mammary ep-
ithelial cell; MIAME, minimal information on microarray ex-
periment; mRNA, messenger ribonucleic acid; NCCR, national
center of competence in research; PCR, polymerase chain re-
action; PI3K, phosphoinositol 3-phosphate kinase; PPAR°, per-
oxisome proliferator-activated receptor ° ; PR, progesterone re-
ceptor; PrlR, prolactin receptor; QRT-PCR, quantitative reverse
transcriptase polymerase chain reaction; RANKL, receptor acti-
vator of nuclear factor-•B ligand; RDA, representational differ-
ence analysis; SSH, subtractive suppressive hybridization; STAT,
signal transducer and activator of transcription; SVP, seminal vesi-
cle protein; TIGR, the institute for genome research; WAP, whey
acidic protein; Wt, wild type.
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such as the JAK2/Stat5 (7–9), the MAP kinase (10),
and PI3K/AKT pathways (11).
In the mammary gland, prolactin signaling
in the epithelium controls the formation of alve-
oli and the differentiation of mammary epithe-
lial cells (MECs) into milk-secreting cells (12).
Moreover, prolactin indirectly affects ductal side
branching through the stimulation of progesterone
secretion by the corpora lutea (13). Prolactin
is also synthesized locally in the breast epithe-
lium (14); this production may be important for
cell proliferation during late pregnancy (15). Lo-
cal prolactin synthesis as well as expression of
the PrlR is upregulated in breast carcinomas
(16), suggesting that localized deregulation of pro-
lactin signaling may contribute to breast carcino-
genesis. Consistent with this notion are observa-
tions that blocking prolactin signaling interferes
with the growth of various breast cancer cell
lines (17,18) and that mice lacking the prolactin
gene show a delay in polyoma middle-T antigen-
induced breast tumorigenesis (19). Furthermore, high
serum prolactin levels have been related to an in-
creased relative risk of developing breast cancer
(20).
How can one hormone ensure milk production,
control uterus, and ovaries, and affect the physiology
of T cells and hair follicles?
A number of mechanisms may be responsible
for these contrasting, tissue-specific effects. Different
forms of prolactin have been described (21) and dif-
ferent receptor forms exist with distinct cytoplasmic
lengths, which may differentially activate distinct in-
tracellular signaling pathways (22). The expression of
receptor and ligand isoforms in cell-type-specific con-
stellations may contribute to the tissue-specificity of
prolactin action. Alternatively, a very similar stimu-
lus may elicit different biological responses in differ-
ent target cells, the signaling networks of which are
wired in distinct ways. This latter hypothesis is sup-
ported by our recent finding that a chimeric recep-
tor consisting of the signaling domain of the erythro-
poietin receptor could, when coupled to the ligand
binding domain of PrlR, rescue the defective alve-
ologenesis and differentiation of PrlR¡=¡MECs (23).
Recent studies exploiting new techniques for tran-
scription profiling lend further support to this hypoth-
esis. Our analysis of transcription profiling studies,
albeit preliminary, suggest that the tissue/cell-type-
specific responses at the transcriptional level differ
substantially.
KNOWN TRANSCRIPTIONAL TARGETS
OF PROLACTIN
In an early differential screening experiment,
interferon-regulatory factor 1 (IRF-1) was identified
as an immediate-early gene in prolactin-stimulated
T cells (24). In hepatocytes, prolactin regulates tran-
scription of the NaC/taurocholate cotransporter (25).
Furthermore, prolactin induces estrogen receptor ex-
pression (26) and progesterone secretion in the cor-
pus luteum (CL) during pregnancy. It also represses
transcription of 20-fi-hydroxysteroid dehydrogenase,
which plays a role in pregnancy termination in the
rat (27). Another molecule known to be involved
in progesterone synthesis, 3fl-hydroxysteroid dehy-
drogenase (3fl-HSD), is also regulated by prolactin
in the CL (28). In NIH-3T3 cells, prolactin stim-
ulates the transcription of the transcription factors
CCAAT enhancer-binding protein (C/EBP) and per-
oxisome proliferator-activated receptor ° (PPAR° )
(29); these effects may explain its adipogenic function
in these cells.
In the mammary gland, prolactin regulates tran-
scription of milk proteins, such as casein (30), whey
acidic protein (WAP) (31) and fl-lactoglobulin (32).
The hormone regulates the transcription of a number
of other genes in various human breast cancer cell
lines. BRCA1 transcription increases in MCF-7 and
T47-D cells following treatment with prolactin (33),
and cyclin D1 is induced in T47D cells (34). Additional
prolactin target genes were discovered using mouse
MEC lines, such as the p100 coactivator in HC11 cells
(35) and the CBP/p300 transactivator Cited4 in SCp2
cells (36).
DISCOVERING NOVEL MEDIATORS
OF PROLACTIN ACTION THROUGH
TRANSCRIPT PROFILING
Considering the variety of biological functions,
the number of target genes identified is limited. How
does prolactin trigger alveolar morphogenesis? What
is the role of prolactin signaling in breast carcinogen-
esis? How does it affect other organs? One way of
addressing these questions is to examine changes in
gene expression induced by activation of the prolactin
signaling cascade in different contexts. With the ad-
vent of microarrays, the research community has a
powerful tool for surveying at once all known mRNA
transcripts in a broad, unbiased fashion. Several
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studies have now been published using arrays, some of
them with more limited transcript sets, to learn more
about genes transcribed following prolactin action in
different biological processes.
PROSTATE
Using a mouse model in which prolactin is
overexpressed from the metallothionine promoter,
Dillner and colleagues (37) looked for genes that
may be important for the prostate hyperplasias seen
in these transgenic animals. cDNA from dorsolateral
and ventral lobes of 4 transgenic and 5 control mice, at
4–6 months of age, was compared. Representational
difference analysis (RDA) identified 152 unique se-
quences, 69 of which had been annotated previously
while 83 sequences were novel. These 152 sequences
were printed on microarrays to which total RNA
from hyperplastic and control prostate tissue was co-
hybridized. Thirty percent of the sequences, i.e. 48 dif-
ferent transcripts, were detected in the starting pool of
total RNA. Thirty-one percent of these, i.e. 15, were
identified as significantly modulated, 10 of them were
annotated. Muscle creatine kinase, vimentin, and cy-
tochrome C oxidase polypeptide III were upregulated
and cytokeratin 8, aldose reductase and RIL protein
downmodulated in the transgenic prostates.
Robertson et al. (38) studied the role of prolactin
in the growth of the normal and cancerous prostate
of PrlR¡=¡ mice by transcript profiling the dorsal and
ventral lobes of prostates from 50-week-old animals.
RNA was collected from five to eight lobes for each
homozygous mutant and wild-type (wt) mouse. Mor-
phological analysis of the prostates from these ani-
mals demonstrated that prolactin plays a subtle role
in the morphogenesis of the prostate, since PrlR¡=¡
animals displayed a 20% increase in prostate weight
and a reduced epithelium content, but no alteration
in branching morphology. Three experiments using
Affymetrix microarrays were performed on the ven-
tral prostate. As triplicates were not substantially
more informative than duplicates, only two experi-
ments were performed on the dorsal prostate. Genes
identified as differentially expressed between PrlR¡=¡
and PrlRC=C prostates are shown in Table I.
The majority of differentially expressed genes
were decreased in the PrlR¡=¡ tissue, suggesting that
prolactin has overall stimulatory effects on transcrip-
tion in both lobes of the prostate. Surprisingly, the
genes most differentially regulated were found to be
Table I. Genes Differentially Expressed Between PrlR¡=¡ and
PrlRC=C Prostates (38)
Accession # Title Fold change
M92849 Acidic epididymal glycoprotein 1 ¡4.30
M88127 Adenemoatosis polyposis coli ¡0.80
X04673 Adipsin ¡1.80
U03419 Alpha-1 type I procollagen ¡0.80
X67140 ATPase, CaCC transporting ¡2.60
V00727 c-Fos 2.50
X61232 Carboxypeptidase H ¡0.90
AV381191 Carcinoembryogenic antigen 10 ¡35.00
L38422 Carcinoembryogenic antigen 10 ¡27.00
AI842667 Cathepsin D ¡1.20
J04953 Gelsolin ¡0.77
M55561 HE5 epididymal glycoprotein ¡1.80
X60676 HSP47 ¡1.70
U69262 Matrillin-2 ¡0.83
AJ223361 Myosin heavy chain 2B ¡7.50
M57683 PDGF receptor, alpha polyeptide ¡4.20
X58251 Procollagen, type 1, alpha 2 ¡1.60
Z18272 Procollagen, type VI, alpha 2 ¡1.80
D10214 Prolactin receptor ¡5.70
D10214 Prolactin receptor ¡2.95
M22957 Prolactin receptor ¡6.70
M60474 Protein kinase C substrate ¡1.30
X15789 Retinoic acid binding protein ¡1.17
X91270 Semenoclotin ¡3.60
L44117 Seminal vesicle autoantigen ¡121.00
M35732 Seminal vesicle protein IV ¡16.00
X57139 Seminal vesicle proteinV ¡7.40
AJ005559 Small proline rich protein 2A ¡10.20
U19486 SVSP99 ¡13.00
L48989 Troponin T3, skeletal, fast ¡3.00
M28729 Tubulin alpha 1 ¡1.70
AI465965 Zonadhesin ¡4.00
involved in fertility. Two subgroups were apparent.
The first involved genes encoding proteins that medi-
ate sperm–egg interactions, such as acidic epididymal
glycoprotein HE5 and zonadhesin. Acidic epididymal
glycoprotein is an androgen-regulated gene secreted
by the epithelium of the epididymis that is thought to
be involved in sperm–oocyte plasma membrane fu-
sion (39–41). It is found on maturing spermatozoa and
shows variable surface presentation during sperm ca-
pacitation (42). Zonadhesin is a sperm-zona pellucida
binding protein that confers species specificity (43).
The second subgroup contains the anti-inflammatory
and procoagulant seminal vesicle proteins, which play
a role in copulatory plug formation and protection
of sperm from the female immune response: namely
SVP2/SV-IV, the semenoclotin and seminal vesicle F
protein/SVP5 (44–46). The changes in the expression
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of these fertility-related genes prompted the authors
to examine the fertility of PrlR¡=¡ males. They found
overall reduced fertility, a prolonged latency to first
pregnancy and a 40% probability to produce a first
pregnancy compared to PrlRC=C animals. This study
demonstrates that transcript profiling can assist in
identifying phenotypes in mutant mouse strains.
OVARY
Stocco and colleagues asked the question
whether prolactin and prostaglandin F2fi (PGF2fi),
which have opposing effects on the corpus luteum,
control the expression of the same genes in an antag-
onistic fashion (47). Pregnant rats were hypophysec-
tomized on day 4 of pregnancy and injected with pro-
lactin or vehicle. Both groups were sacrificed 7 days
later, and RNA was isolated from CL. Out of the 1176
distinct rat genes on the cDNA microarrays, 13 were
controlled by both prolactin and PGF2fi in opposite
fashion. The 27 genes identified as differentially reg-
ulated by prolactin are listed in Table II.
Table II. Genes Regulated by Prolactin in the Corpus Luteum (47)
Accession # Title Annotation
L12382 ADP-ribosylation factor 3 Genes downregulated
Annexin V by prolactin
X17163 c-jun
20a-HSDa
U47287 PGF2 alpha-Ra
M20637 Phospholipase C d1a
X52498 TGF beta1a
P450scc Genes upregulated
3b-HSD by prolactin
SR-B1
Beta2-microglobulin
L31884 TIMP2
X14209 Cytochrome c oxidase IV
M36320 Cathepsin H
Y00697 Cathepsin L
Cu/Zn SOD
L29259 Elongation factor SIII
HSP60
D10021 ATP synthase D
M26199 LH-Ra
U22424 11b-HSD2a
MGSTa
GST m2a
D10862 Id1a
D10863 Id2a
D10864 Id3a
M86870 Calcium binding protein 2a
aGenes that are antagonistically regulated by prolactin and PGF2fi.
Nb2 RAT LYMPHOMA CELLS
Bole-Feysot et al. (48) used the rat Nb2-11c lym-
phoma cell line, which depends on prolactin for pro-
liferation, to identify Prl target genes. By means of
mRNA differential display, RDA, subtractive sup-
pressive hybridization (SSH), analysis of weakly
expressed genes and screening of an organized li-
brary, they identified 70 genes that were differen-
tially transcribed by Nb2-11c cells within 2–24 h
of prolactin treatment. Twenty of these were un-
known; the other 50 genes were classified to 10
functional categories, such as cell cycle regulators,
nucleotide metabolism/DNA replication and repair
proteins, cell-surface antigens/adhesion proteins, sig-
naling moleciles involved in apoptosis or prolifera-
tion, or transcription factors (see Table III).
UTERUS
Deletion of the PrlR in mice causes female in-
fertility and failure of implantation (49). Applying
mRNA differential display to PrlR¡=¡ and wt uteri
implantation sites, Baran et al. isolated 45 transcripts,
out of which 29 corresponded to known mouse ESTs
(see Table IV) (50).
MAMMARY GLAND
To identify new prolactin target genes in the
mammary gland, Hou et al. made use of mice that are
homozygous for a disrupted prolactin allele (Prl¡=¡)
(51). Prl¡=¡ females are infertile but their mammary
glands develop a normal ductal system. The authors
compare RNA from Prl¡=¡ and PrlC=¡ mammary
glands from 10-week-old females, pooled from five
mice of each genotype. One hundred seventy-nine
out of 588 transcripts represented on the Clontech
membrane were detected (30%), 33 (18%) were el-
evated in the PrlC=¡ mammary glands, and 7 (4%)
were elevated in Prl¡=¡ mammary glands. The au-
thors focused on one particular gene, the expression of
which was decreased in the Prl¡=¡ mammary glands,
the glycosylation-dependent cell adhesion molecule 1
(GlyCAM1). Immunohistochemistry confirmed that
GlyCAM1 protein is expressed in the mammary ep-
ithelium and the ductal lumen of PrlC=¡ virgin mice. In
the mouse mammary epithelial cell line HC11, which
can be induced to express milk proteins in vitro, Gly-
CAM1 mRNA is increased after 48 h of prolactin and
progesterone treatment. An 800 bp fragment of the
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Table III. Transcripts Modulated by Prolactin in the Rat Nb2-11c Lymphoma Cell Line (48)
Title Annotation Title Annotation
Cyclin E1 Myosin heavy chain Cytoskeleton
EGR-1 Transcripts that have a Tubulin, a, b
Cdc5-like protein cell-cycle modulated Beta-actin
Cdk2, Cdk5 homolog in yeast FAKp125
Cyclin B1 Cell-cycle-modulated IRF-1 Transcription factor
Cyclin B2 transcripts with a yeast c-Myc
Cyclin D2 homolog (not modulated) c-Fos
Cyclin D3 MRG1-related protein
Cdc21 homolog Nucleotide metabolism, E2F-1
Spermidine N-acetyl DNA replication and Zfx
Ornithine decarboxylase repair Cyclophilin Heat shock, stress response
S-adenosylmethionine TCP-1 e and h and chaperones
Prothymosin a Hsp70
PARP-2 Hsp70-like D Nb29
Prolactin receptor Surface molecules Hsp27
T-cell receptor gamma chain Hsp86
GnRH receptor Beta-actin
Glucocorticoid receptor Alpha2-tubulin
Galectin-8 Rdnuc
CD45 Myosin heavy chain
Vitamin D3 receptor Focal adhesion kinase
Thromboxane A2 Phosphoglycerate kinase Metabolism
Beta2-microglobulin Enolase a
p38 Map kinase Signaling molecules Aldehyde dehydrogenase
Pim-1 ATP synthase beta subunit
Gfi-1 L15 type Ribosomal proteins
Stathmin S8, S13
P13 kinase p110a Itm1 Glycosylation factor
Phospholipase Cy1 EF-2 Elongation factor
14-3-3 h and e CRM-1
Bax Sec-22 Intercompartment
p53 Glycine transporter transport and trafficking
RexB/NSP FGF-responsive Unknown function
Phosphatidylinositol Histones H2A, H2B Chromatin Structure
Alpha 4 phosphoprotein FGF-2 Growth Factor
GlyCAM1 promoter, in front of a luciferase gene,
gives a threefold increase of luciferase activity in the
presence of prolactin. Thus, the microarray approach
allowed the authors to identify a new prolactin target
gene in the mammary epithelium. The biological im-
portance of GlyCAM1 in mediating the response to
prolactin remains to be evaluated.
Using organ cultures, Naylor et al. demonstrated
that the neuropeptide galanin acts on the mammary
gland to ensure final stage differentiation and milk se-
cretion (52). Transcript profiling of explants treated
with either galanin, prolactin, or both factors was per-
formed. The genes identified as transcriptionally reg-
ulated by either factor or both are listed in Table V.
Among them were milk protein genes, markers of
MEC differentiation, and several known JAK/STAT
target genes.
The observation that some genes were regulated
exclusively by prolactin and galanin in conjunction
suggests that the two hormones can act synergistically
in addition to having independent actions.
The overall number of genes regulated by pro-
lactin was larger than the number of genes regulated
by galanin. This result suggests that prolactin has a
much stronger effect on transcription in the mam-
mary gland than galanin. Interestingly, prolactin and
galanin have opposite effects on the transcription lev-
els of some of the genes which are regulated by both
of them, reflecting the complexity of the interactions
occurring in the mammary gland organ cultures fol-
lowing galanin and prolactin treatments.
As discussed above, prolactin acts as a potent
mitogen and morphogen on the mammary epithe-
lium in vivo (53), but the mechanisms by which it
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Table IV. Differentially Expressed Transcripts in the PrlR¡=¡
Uterus at Day 5.5 of Pregnancy (50)
Accession # Title Annotation Change
AK011085 HSPC 307 Immunity C
AF039584 Decay accelerating ¡
factor precursor
AE000664 T cell receptor beta ¡
AJ242912 Disintegrin C
metalloprotease
AJ133291 Calpain 7 ¡
AJ251880 MTF-1 Machinery ¡
BG063008 TIS ¡
U57343 Meis 2 ¡
X70398 Neuronal protein ¡
AK014555 KIAA0056 ¡
C88153 Rapamycin binding ¡
protein
AK011778 FK506 binding ¡
protein
AW3211326 Retinoblastoma C
binding protein
BC002185 SCAMP1 Cell ¡
components
AF105268 Glypican-6 C
L49502 Phosphoprotein ¡
D10837 Lysyl oxidase ¡
BC005503 Protein FLJ1 ¡
AK018731 Ribosomal protein ¡
L24
AK005722 Glutathione ¡
S-transferase
AF242319 Endosomal protein ¡
AF362729 Ion transport C
regulator CHIF
A1648789 Immunoglobulin Cell cycle C
binding protein 2
AB030204 Integral membrane ¡
protein E25B
AJ130977 Ariadne protein ¡
BJ797450 Sterol Metabolism ¡
O-acyltransferase 1
AF017175 Carnitine
palmitoyltransferase 1
AI853806 Glutamate receptor, ¡
AMPA 1
induces cell proliferation remain unclear. We showed
that the cell cycle protein, cyclin D1, is required in
the mammary epithelium for prolactin-induced alve-
ologenesis. While prolactin application to primary
MECs induced only a low level of cyclin D1 syn-
thesis, longer exposures—18 h—led to a significantly
higher cyclin D1 protein expression (54). These ob-
servations suggested that prolactin might be induc-
ing the expression of an intermediate growth factor,
which in turn induced cyclin D1 and proliferation. To
identify such a growth factor, we conducted a screen
that selects specifically for genes that function down-
stream of the PrlR and upstream of cyclin D1 (54). We
compared the transcription profiles of pairs of con-
tralateral cleared inguinal mammary fat pads, which
had been reconstituted with PrlR¡=¡ or cyclin D1¡=¡
MECs. The host mice were wt. At 3 weeks of age,
their inguinal fat pads were surgically cleared of en-
dogenous epithelium and engrafted with MECs from
PrlR¡=¡ and cyclin D1¡=¡ females. As first shown by
DeOme (55), such epithelial grafts can reconstitute
the mammary stroma, forming a new ductal system.
Four weeks later, when the grafts had fully penetrated
the fat pad, the hosts were mated. Since the morpho-
genetic block shown by MECs of these two genotypes
are similar, these two types of mammary glands, as-
sayed at an identical day of pregnancy, are presumed
to carry comparable numbers of cells in comparable
states of proliferation. The only differences in gene ex-
pression pattern between them should involve those
genes that lie downstream of PrlR signaling and up-
stream of cyclin D1 expression.
Out of the 6500 transcripts surveyed, 319 were
expressed at more than threefold higher levels in the
cyclin D1¡=¡ than in the PrlR¡=¡ grafts, whereas 430
transcripts were downregulated more than threefold.
Previous observations had indicated that, in contrast
to the PrlR¡=¡ epithelium, the cyclin D1¡=¡ epithe-
lium retains its ability to undergo differentiation, as
manifested by its ability to synthesize milk proteins
late in pregnancy (56). Accordingly, many genes en-
coding proteins secreted with the milk or involved
in milk production, such as metabolic enzymes, cal-
cium transport genes, and intracellular vesicular traf-
ficking genes, were differentially expressed, with their
transcripts being found at far higher levels in the cy-
clin D1¡=¡ grafts than in the fat pads engrafted with
PrlR¡=¡ MECs. In addition, genes involved in signal
transduction and in the construction of the cytoskele-
ton and the extracellular matrix (ECM) were prefer-
entially expressed in the cyclin D1¡=¡ recombinants.
An overview of the genes whose expression lev-
els differed by more than 10-fold is given in Ta-
ble VI. We concentrated our further analysis on
one of the secreted factors that were particularly
highly expressed in the cyclin D1¡=¡ grafts, namely
insulin-like growth factor-2 (IGF-2), which was found
at a level 13.2-fold higher in the glands engrafted
with cyclin D1¡=¡ epithelia than in their PrlR¡=¡
counterparts. QRT-PCR showed a 30-fold differ-
ence. Consistent with a model in which prolactin
relies on a secreted factor IGF-2 to induce a pro-
liferative response, we found that prolactin induces
IGF-2 mRNA expression in primary MECs and
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Table V. Genes Found to be Regulated by Prolactin in Mammary Gland Organ Cultures (52)
Accession # Title Annotation Change
V00856 Whey acidic protein Milk protein C
M36780 Casein alpha C
D10215 Casein gamma C
X04490 Casein beta C
M87863 Alpha lactalbumin C
M10114 Casein kappa C
V00740 Casein delta C
X93037 WDMN1 C
M93428 Glycosylation depend. cell adhes. mol. 1 Cell adhesion C
U03419 Procollagen, type 1, alpha 1 C
X58251 Procollagen, type 1, alpha 2 C
X60367 Cellular retinol binding protein 1 Retinol metabolism C
AF049702 E74-like factor 5 Transcription factor C
Y07688 Nuclear factor I/X Transcription factor C
X04480 Insulin-like growth factor 1 Growth factor C
M31680 Growth hormone receptor GH signalling C
L12447 IGF binding protein 5 IGF signalling C
M38337 Milk fat globule-EGF factor 8 Cell adhesion C
X95279 Spot 14 Lipogenesis C
M81445 Connexin 26 Gap junction C
AF077861 Helix–Loop–Helix inhibitor protein id2 Transcription inhibitor C
X16490 Plasminogen activator inhibitor 2 Protease inhibitor ¡
M33960 Plasminogen activator inhibitor 1 ¡
D10837 Ras recision gene Tumour suppressor ¡
M19681 PDGF-inducible protein (JE) gene Chemoattractant C
D29678 Cyclin-dependent kinase 5 Cell cycle C
L42115 Solute carrier family 1, member 7 Transport C
U82758 Claudin 5 Tight junction C
AI154710 Zinc finger protein 125 DNA binding ¡
D50311 Myocyte enhancer factor 2B Transcription regulator ¡
M57683 PDGF receptor beta Tyr kinase receptor C
L19932 Beta ig-h3 Cell adhesion inhibitor C
J02872 Granzyme G Proteolysis ¡
L32838 Interleukin 1 receptor antagonist ILR1 signalling C
D38046 Topoisomerase (DNA) II beta DNA metabolism ¡
X83934 Ryanodine receptor 3 Calcium homeostasis C
AV362816 Steroidogenic acute regulatory protein Steroid hormone biosyn ¡
that IGF-2 in turn can induce expression of cyclin
D1 protein. In the absence of IGF-2 from the mam-
mary epithelium, alveologenesis is delayed. Ectopic
expression of IGF-2 in PrlR¡=¡ epithelium rescues the
proliferative defect, arguing that IGF-2 is a physiolog-
ically important mediator of prolactin-induced pro-
liferation/morphogenesis. Hovey et al. independently
drew the same conclusion based on transcript quan-
tification in PrlR¡=¡ mouse mammary glands (57).
Certainly, more can be learned from the data
obtained with this screen. Another growth factor
found to be differentially expressed is HB-EGF (Gass
and Brisken, unpublished observations), and its role
in alveologenesis remains to be studied. In further
exploring the data, we need to be aware of several
potential limitations of our approach. This screen is
based on the assumption that the genes expressed at
higher levels in the fat pads reconstituted with cyclin
D1¡=¡ epithelium than in the fat pads reconstituted
with PrlR¡=¡ epithelium are transcriptionally acti-
vated by prolactin signaling. However, it is formally
possible, that differences in gene expression levels are
independent of prolactin signaling and result instead
from a lack of cyclin D1-dependent repression. This
concern can be addressed by comparing expression
levels in cyclin D1¡=¡ versus cyclin D1 wt transplants,
as done for IGF-2. More general limitations, such as
the choice of genes arrayed and the sensitivity, are
discussed below.
We used a novel approach to elucidate the tran-
scriptional response to prolactin specifically in the
mammary gland during early pregnancy. By transcript
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Table VI. Genes Expressed at a 10-Fold Higher Level in PrlR¡=¡ Mammary Epithelial Transplants than Cyclin
D1 Transplanted Glands (54)
Accession # Title Annotation
X93037 WDNM1 Milk secretion
W18308 Ferritin heavy chain gene
X04673 Adipsin
X61431 ACYL-COA-binding protein
Y00516 Fructose-bisphosphate aldolase A
M32599 Glyceraldehyde-3-phosphate dehydrogenase
AA071776 Phosphoglucose isomerase
J05277 Hexokinase
X04490 Casein beta
L09104 Glucose phosphate isomerase
M21285 Stearoyl-Coa desaturase
AA117004 KDEL receptor
X02520 Lactate dehydrogenase 1, A chain
W09506 Fatty acid-binding protein
X97991 Calcitonin Calcium metabolism
M27844 Parvalbumin
W20937 Calcium-transporting atpase sarcoplasmic reticulum type
X51438 Vimentin Cytoskeleton
AA168865 Actin 1 (fragment)
J04953 Gelsolin
X14425 Profilin 1
U20365 Muscle gamma actin
AA002605 Insulin-like growth factor II Growth factors
X04017 SPARC Extracellular matrix
X14194 Nidogen
X17069 COL1A2
X65582 Procollagen, type VI, alpha 2
U08020 Alpha 1 type I collagen gene
ET61037 Lectin
X72862 Beta-3-adrenergic receptor
X73523 Matrix G1a protein
W75072 Procollagen, type IX, alpha 2
X15358 Insulin-like growth factor binding protein 4 Signal transduction
W65899 Guanine nucleotide-binding proteinbeta subunit 2
D10024 Calpactin I heavy chain
X58251 E-selectin ligand-1
L23108 GTP-binding protein
X85788 DCC tumour suppressor
L09192 Cathepsin D
M16358 RAB1
AA163643 Heat shock cognate 71 KD Heat shock
U73744 Heat shock 70
AA105022 Heat shock protein HSP 90-beta
W41817 C oxidase subunit VIII precursor Miscellaneous
Z83368 RPS3a
M76131 Elongation factor 2
X54691 Cytochrome C oxidase, subunit IV
W88176 Thiol-specific antioxidant protein (PRP)
Z50159 Sui 1
M24263 Testosterone 16-alpha-hydroxylase gene
AA138107 COX7c1
D10024 Apolipoprotein E
X82067 Thioredoxin-dependent peroxide reductase
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profiling PrlR¡=¡ and PrlRC=C epithelial transplants
during early pregnancy, we reduced the effect of dif-
ferences in epithelial cell number seen during late
pregnancy, when PrlR¡=¡ epithelium fails to form
alveoli. Additionally, we examined transcript profiles
of PrlRC=C mammary fat pads cleared of epithelium
to distinguish transcripts present in the epithelium
from those in the fat pad. The profiling was performed
with pools of RNA from four to six animals on high-
density oligonucleotide arrays (Affymetrix MGU74A
GeneChips). Data were analyzed using MicroArray
Suite 4.0 (MAS 4.0 Affymetrix) and sorted using Ex-
cel (Microsoft). Fold changes, calculated by MAS 4.0
for a number of genes were confirmed by quantitative
PCR using the LightCycler (Roche). Overall, there
was a dramatic loss of expression in the PrlR¡=¡ ep-
ithelial transplants at all 3 days of pregnancy profiled
(days 2, 4, and 6), including epithelial markers such
as keratins. Nevertheless, merely 15% of “epithelial
transcripts,” as defined by their presence in PrlRC=C
transplants and concomitant absence from PrlRC=C
cleared fat pads, displayed decreased expression lev-
els in the PrlR¡=¡ transplants. These results suggested
that the changes in gene expression were due to a lack
of prolactin action and not due to differences in ep-
ithelial cell number.
The genes identified by MAS 4.0 were sorted
into groups, depending on their gene ontology as
annotated in NetAffx (Affymetrix). This abbreviated
list (to be published in full elsewhere; Harris et al.,
submitted) does not include cDNAs of unknown
function or genes associated with expressed se-
quence tags (ESTs), which are the focus of ongoing
investigations. Extensive literature searches suggest
that many of the genes whose expression decreased
in PrlR¡=¡ transplants are usually upregulated
during pregnancy and localize predominantly to the
epithelium.
Thus, four milk protein genes (casein fi, fl, • , and
WDNM1) were decreased in the glands reconstituted
with PrlR¡=¡ epithelium. The isolation of ß-casein,
a known prolactin-regulated gene, confirms that our
model can identify prolactin-regulated genes involved
in MEC differentiation.
The development of the mammary gland is not
only influenced by systemic hormones but also de-
termined by the cell’s microenvironment. One com-
ponent of this environment which helps to deter-
mine tissue-specific gene expression is the ECM
(58). As shown in Table VII, we identified several
ECM components, involved in cell adhesion and
alveolar development as potential prolactin target
Table VII. Genes Reduced in Expression During Early Pregnancy
in the PrlR¡=¡ Mammary Epithelial Grafts (59)
Accession # Title Annotation
X15662 Keratin complex 2, basic, Cytoskeleton
gene 8
M36120 Keratin complex 1, acidic,
gene 19
M13805 Keratin complex 1, acidic,
gene 17
M22832 Keratin complex 1, acidic,
gene 18
U43298 Laminin, beta 3 Cell adhesion
U32107 Procollagen, type VII,
alpha 1
AJ131395 Procollagen, type XIV,
alpha 1
X55123 GATA binding protein 3 Transcription
factor
X94694 Transcription factor AP-2,
gamma
AF09505 Claudin 3 Cell junction
AF087825 Claudin 7
M81445 Connexin 26
AF019048 RANKL Ligand
L41352 Amphiregulin
M89797 Wnt-4
M36780 Casein alpha Milk protein
X04490 Casein beta
M10114 Casein kappa
X93037 WDMN1
genes, including procollagenfi1 type VII and XIV, and
lamininfl3.
Claudins are recently discovered integral mem-
brane proteins that are major structural compo-
nents of tight junction strands. Tight junction clo-
sure increases during lactation to prevent diffusion
of molecules across the mammary epithelium. This
process is mediated by progesterone withdrawal fol-
lowing parturition and requires activation of the PrlR
(59). Our finding that claudin 3 and 7 expression is
decreased in PrlR¡=¡ mammary glands suggests that
prolactin may further influence these junctions by reg-
ulating the transcription of their components.
Connexin-26 is a member of a large family of
proteins that form gap junctions and allow exchange
of small ions between epithelial cells. Connexin-26
mRNA and protein expression are significantly up-
regulated during pregnancy and remain elevated dur-
ing lactation (60); expression is confined to the alveo-
lar epithelium and the protein localizes to sites of cell
contact (61).
Our screen also identified several secreted lig-
ands of importance for cell–cell communication
and cell differentiation. One such gene, Wnt-4, is a
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member of the Wnt family of secreted glycoproteins
implicated in cell–cell signaling. We have shown that
Wnt-4 acts downstream of progesterone to induce
ductal side-branching during pregnancy (62). Over-
expression of Wnt-4 in the mammary gland by retro-
viral delivery resulted in increased ductal side branch-
ing and alveolar-like structures in virgin animals (63).
Another gene of interest, amphiregulin, is a member
of the epidermal growth factor (EGF) family, whose
members bind to the EGF receptor family. In mice
lacking both amphiregulin alleles, the ductal tree fails
to fully penetrate the fat pad. Ectopic expression of
amphiregulin in the mammary epithelium can result
in hyperplastic ducts and lobules (64). Finally, tumor
necrosis factor (ligand) superfamily member 11, also
known as receptor activator of nuclear factor-•B lig-
and (RANKL) and osteoprotegrin ligand, was found
to be decreased in the PrlR¡=¡ epithelium at all three
time points. The mammary glands of RANKL¡=¡
mice, similar to PrlR¡=¡ mammary glands, fail to de-
velop alveoli, resulting in lactational failure in the
mutant animals. Our preliminary studies have shown
that prolactin modulates RANKL expression during
early pregnancy, suggesting that prolactin is the mas-
ter regulator of signaling events necessary for alveolar
development.
Interestingly, all three, Wnt-4 (62), amphiregulin
(65), and RANKL (54), are known targets of proges-
terone signaling. It remains to be seen whether they
are also direct prolactin targets or whether their ex-
pression is indirectly controlled by prolactin. Grimm
et al. (66) demonstrated that PrlR¡=¡ mammary ep-
ithelial grafts showed increased progesterone recep-
tor expression compared to their wt counterparts and
a decrease in proliferation after combined estrogen
and progesterone treatments. These findings suggest
that progesterone response of the mammary gland is
altered in the absence of prolactin signaling. Further-
more, studies by Hovey et al. (79) demonstrate that the
PrlR and progesterone receptor (mRNA) show simi-
lar expression patterns, and synergistic effects of both
hormones arguing further for cross talk of these two
signaling pathways.
Eventually, a number of transcription factors
were discovered to be important for the prolactin-
stimulated development of alveolar cells, among them
the GATA binding protein 3, a member of a family
of transcription factors that bind to DNA through a
highly conserved zinc finger domain.
Thus, these transcript profiling experiments show
that, in addition to the induction of milk proteins at
the late stage of differentiation, prolactin also induces
the transcription of genes important for intracellular
and extracellular structure, cell permeability, cell–cell
communication, and differentiation.
COMPARISON OF THE DIFFERENT SCREENS
The recent studies presented above have applied
expression profiling techniques to investigate the in-
fluence of prolactin on transcription in different tis-
sues or cell lines and have generated a list of puta-
tive prolactin targets. Our comparison of the genes
identified indicates that few of them are common to
different tissues (see Table VIII and Table IX).
As illustrated by the Venn diagram in Fig. 1,
among the different organs studied, mammary and
prostate glands displayed the largest overlap in puta-
tive prolactin target genes. Three of the genes shared
between these two were equally modified in the ovary;
these code for proteins of the cathepsin, cytochrome
c oxidase, and annexin families. On the other hand,
transcription of genes coding for elongation factors
of the E2F family was affected in the ovary, Nb2
cells and the mammary gland, whereas phospholipase
genes were differentially transcribed in the prostate,
the ovary, and the lymphoma cell line Nb2. The mean-
ing of these findings remains open for speculation.
Cathepsins are lysosomal cysteine proteases that
are optimally active in the slightly acidic-reducing mi-
lieu of lysosomes and that participate in the degra-
dation of lysosomal proteins (67). Several members
of the cathepsin family, such as cathepsin B and D,
were found to be involved in the processes of apop-
tosis, tumor invasion, or metastasis (68), and their in-
creased expression is correlated with poor prognosis
in colorectal carcinoma (69). Interestingly, cathepsin
L was also reported to play an active role in mouse
mammary gland involution (70). It is conceivable that
cathepsins play a role in tissue remodeling in the
prostate and the mammary gland, both of which are
organs that undergo extensive branching morphogen-
esis during their hormonally controlled development.
Annexins are Ca2C and phospholipid-binding
proteins, members of a conserved multigene family
which are expressed throughout animal and plant
kingdoms. They are known to participate in the reg-
ulation of membrane organization, membrane traffic,
Ca2C ion currents across membranes, and intracellular
Ca2C concentrations. Annexin II and V were shown to
play roles in heart diseases, coagulation, cell growth,
and transformation. Moreover, annexins promote in-
sulin secretion and induce secretion in neutrophils,
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Table VIII. Genes Common to Two or More Genomic Screens Outlined in This Paper
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M81445 Connexin 26 Gap Junction ⁄ ⁄
AJ223361 Myosin heavy chain 2B Cytoskeleton ⁄ ⁄
J04953 Gelsolin ⁄ ⁄
X15662 Keratin complex 2, basic, gene 8 ⁄ ⁄
M28729 Tubulin alpha 1 ⁄ ⁄
X51438 Vimentin ⁄ ⁄
X04490 Casein beta Milk protein ⁄ ⁄ ⁄
X04673 Adipsin ⁄ ⁄
X93037 WDMN1 ⁄ ⁄ ⁄
L09104 Glucose phosphate isomerase ⁄ ⁄
M93428 GlyCAM 1 Cell adhesion ⁄and Hou et al.
U03419 Procollagen, type 1, alpha 1 Extracellular matrix ⁄ ⁄ ⁄
X58251 Procollagen, type 1, alpha 2 ⁄ ⁄ ⁄
X65582 Procollagen, type VI, alpha 2 ⁄ ⁄
Beta2-microglobulin Surface molecules ⁄ ⁄
V00727 c-Fos Transcription factor ⁄ ⁄
AI842667 Cathepsin D Protease ⁄ ⁄
AF077861 Inhibitor protein ID2 Transcription inhibitor ⁄ ⁄
AA002605 Insulin-like growth factor II Growth factors ⁄ ⁄ H
ov
ey
et
al
.
M57683 PDGF receptor alpha Tyr kinase receptor ⁄ ⁄
M20637 Phospholipase C d1 Signalling molecule ⁄ ⁄
T-cell receptor Immunity ⁄ ⁄
M76131 Elongation factor 2 Miscellaneous ⁄ ⁄
both in presence of Ca2C (71). The modulation of an-
nexin genes in prostate and mammary gland may re-
late to the secretory function of both organs.
In view of prolactin’s function as a morphogen
and differentiation inducing factor, it is easy to ratio-
nalize that several genes involved in protein synthesis,
such as elongation factor 2 and different ribosomal
proteins, are upregulated by the hormone in several
target tissues. The prominent induction of cytochrome
C oxidase subunits and heat shock proteins, however,
remains puzzling to us.
Id proteins (Inhibitor of differentiation or In-
hibitor of DNA-binding), differentially transcribed
in ovary and mammary glands, are proteins acting
as dominant negative inhibitors of differentiation-
specific basic Helix–Loop–Helix transcription factors.
They inhibit cellular differentiation and induce prolif-
eration by modulating different cell cycle regulators,
by both direct and indirect mechanisms (72). Recent
reports show that Id proteins are overexpressed in
various cancers (73). The mammary glands of Id2¡=¡
mice fail to form alveoli during pregnancy (74).
Several of the genes mentioned have been im-
plied to play a role in tumorigenesis; their transcrip-
tional modulation by prolactin is suggestive of a rela-
tionship between this hormone and cancer.
In addition to the above-mentioned candidates,
genes encoding cytoskeletal proteins were widely rep-
resented in prostate and mammary gland studies. This
observation can be explained by the nature of the
molecules. Indeed, transcription factors and signal-
ing molecules tend to be expressed at low levels, so
expression per se or changes in expression may not
be detected. On the contrary, cytoskeletal proteins
and corresponding mRNAs are much more abun-
dant, simplifying their detection and making changes
in their expression levels easy to reveal.
While few genes were common targets of pro-
lactin, a large number of genes were specifically
modulated in any given organ, arguing either for a
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Fig. 1. Venn diagram presenting the total numbers of putative prolactin target genes
in different systems. Note. Phospolipase genes, and ribosomal proteins, identified as
differentially expressed in ovary-uterus, prostate and NB2 lymphoma cells, are not
represented here.
tissue-specific expression pattern or for discrepancies
between the experimental conditions.
LIMITATIONS AND CAVEATS OF THE GENE
EXPRESSION ARRAY APPROACH
The data summarized above have to be consid-
ered carefully for various reasons. First of all, different
systems were used to undertake the expression profil-
ing. Bole-Feysot et al., for instance, used a lymphoma
cell line while the other studies were based on in vivo
models. Cell lines may not conserve the expression
profiles displayed by their in vivo counterparts. In-
deed, recent investigations by Mackay et al. (75) on
expression profiles in different models where ErbB2
was overexpressed, namely tumor biopsies, BT474
cell lines, and ErbB2-transfected cell lines, showed
that there was only one gene, apart from ErbB2 itself,
that was transcribed in an ErbB2-dependent fashion
in all of the models. This result clearly argues for sub-
stantial variations in transcription profiles between in
vivo and in vitro systems.
Moreover, the absence of a gene in a given tissue
may simply be explained by the fact that the corre-
sponding probe was not present on the array used for
the screen. Indeed, different arrays were used; while
Dillner et al. selected 3500 clones out of the TIGR
rat index, Naylor and colleagues screened 36000 full
length mouse genes and ESTs retrieved from the Uni-
gene databank. Obviously, which genes can be identi-
fied depends upon the design of the chip or library that
was screened, the number of genes arrayed, and the
spectrum of functional gene categories. The 91 probes
used by Bole-Feysot et al. in their differential display
experiment were specifically chosen among signaling
molecules and transcription factors, with the assump-
tion that expression of these genes was likely to be
modulated in response to prolactin action. Hence, the
results obtained do not necessarily reflect the overall
actual expression profile, but are biased by this arbi-
trary selection step.
Further discrepancies observed between the
genes listed for each experiment may be due to the
way the data were analyzed. Arbitrarily, different fold
changes were chosen as the thresholds between back-
ground signals and signals that were considered rele-
vant for further analysis (1.5-fold for Dillner and col-
leagues, 10-fold for Brisken et al.) (Table IX).
PERSPECTIVES
The present review allowed us to highlight genes
modulated in various tissues upon prolactin treat-
ment. Some of these genes may be involved in the
potential cancer-promoting role of prolactin. It will be
interesting to test whether they can be used as mark-
ers in breast, prostate, or ovarian cancers.
Our review also raises the issue of the relevance
of microarray data, their validation, and comparison
of the results obtained by different groups. Few sur-
veys have been done to assess the accuracy of ar-
ray data, comparing the results to “laboratory-based
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Table IX. Families of Genes Common to the Genomic Screens Outlined in This Paper
Accession # Title Annotation D
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AJ131395 Procollagen, type XIV alpha 1 Cell Adhesion ⁄
M93428 Glycosylation depend. cell adhes. ⁄
U03419 Procollagen, type 1, alpha 1 ⁄ ⁄ ⁄
U32107 Procollagen, type VII alpha 1 ⁄
W75072 Procollagen, type IX, alpha 2 ⁄
X58251 Procollagen, type 1, alpha 2 ⁄ ⁄ ⁄
X65582 Procollagen, type VI, alpha 2 ⁄ ⁄
M81445 Connexin 26 Cell junction ⁄ ⁄
AF09505 Claudin 3 ⁄
AF087825 Claudin 7 ⁄
U82758 Claudin 5 ⁄
M20637 Phospholipase C Signaling ⁄ ⁄
J04953 Gelsolin Cytoskeleton ⁄ ⁄
M13805 Keratin complex 1, acidic, gene 17 ⁄
M22832 Keratin complex 1, acidic, gene 18 ⁄
M36120 Keratin complex 1, acidic, gene 19 ⁄
X15662 Keratin complex 2, basic, gene 8 ⁄ ⁄
X04673 Adipsin ⁄
X51438 Vimentin ⁄ ⁄
Myosin heavy chain ⁄ ⁄
M76131 Elongation factor 2 Elongation factor ⁄ ⁄
L29259 Elongation factor SIII ⁄
X04480 Insulin-like growth factor I IGF signalling ⁄
AA002605 Insulin-like growth factor II ⁄ H
ov
ey
et
al
.
L12447 IGF binding protein 5 ⁄
X81584 IGF binding protein 6 ⁄
X15358 Insulin-like growth factor binding protein 4 ⁄
U73744 Heat shock 70 Heat shock ⁄
AA163643 Heat shock cognate 71 KD ⁄
AA105022 Heat shock protein HSP 90-beta ⁄
Hsp27 ⁄
Hsp70 ⁄
Hsp86 ⁄
HSP60 ⁄
X60676 HSP47 ⁄
AK011085 HSPC 307
ATP synthase Metabolism ⁄ ⁄
D10215 Casein gamma Milk protein ⁄
L09104 Glucose phosphate isomerase ⁄
M10114 Casein kappa ⁄ ⁄
M36780 Casein alpha ⁄ ⁄
V00740 Casein delta ⁄
X04490 Casein beta ⁄ ⁄ ⁄
X04673 Adipsin ⁄
X93037 WDMN1 ⁄ ⁄ ⁄
X54691 Cytochrome C oxidase, subunit IV Cytochrome C ⁄ ⁄
J01420 Cytochrome c oxidase polypeptide ⁄
L09192 Cathepsin D Cathepsin ⁄ ⁄
M36320 Cathepsin H ⁄
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Table IX. (Continued)
Accession # Title Annotation D
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Y00697 Cathepsin L ⁄
b2-microglobulin Steroidogenesis ⁄ ⁄
D10862 Id1 Transcription ⁄
AF077861 Helix–Loop–helix inhibitor protein id2 Inhibitor ⁄ ⁄
D10864 Id3 ⁄
V00727 c-Fos Transcription factor ⁄ ⁄
M57683 PDGF receptor alpha Tyr Kinase ⁄ ⁄
X04367 PDGF receptor beta Receptor ⁄
M19681 PDGF-inducible protein (JE) gene ⁄
results” using, for instance, Northern Blot or Real-
Time PCR approaches. Taniguchi et al. (76) showed
that microarrays, obtained by designing their own ar-
rays with selected mouse ESTs, and Northern Blot
analyses gave globally consistent results, except for
4 out of 46 genes, their fold change being too low
to be detected by the array. Similarly, Rajeevan and
colleagues (77) demonstrated that genes identified by
DNA array with a two- to fourfold difference in ex-
pression levels could not be accepted as true or false
positive without confirmation by Real-Time PCR ap-
proaches. Microarray analysis may therefore over-
look genes of significant interest because they display
deceivingly small differences in expression levels.
Indeed, as mentioned above, for many signaling
molecules such as transcription factors, small changes
in expression can have significant biological impact.
Furthermore, there is the general problem of microar-
rays, that all the regulatory changes at protein lev-
els are ignored. It is not clear to date whether pro-
tein expression correlates with the transcription level,
as measured on arrays. In fact, preliminary surveys
by the National Cancer Institute to evaluate expres-
sion levels of the corresponding protein products in-
dicate that they correlate in less than 50% of the
cases (see http://www.cancer.gov/tarp). This argues
that proteomics will be more helpful for understand-
ing of the molecular mechanisms involved in differen-
tiation, carcinogenesis, and other biological processes.
Overall these new technologies, such as comparative
expression profiling using polysome-bound mRNA,
yield a better representation of the proteome than ex-
pression profiling employing total mRNA (see issue
of Journal of Mammary Gland Biology and Neoplasia,
Vol. 7, October 2002, for more detailed information).
The development of widely accepted and appli-
cable standards, such as the MIAME (Minimal infor-
mation on Microarray Experiment), that will enable
meaningful comparison of array data between differ-
ent research groups, the development of uniform val-
idation methods, and a more complete understanding
of how to compare and contrast results derived by dif-
ferent techniques, are therefore of great interest (78).
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